Department of Respiratory Disease, No.323 Hospital of PLA, Xi'an, Shaanxi 710054, China.
J Tradit Chin Med. 2012 Jun;32(2):203-7. doi: 10.1016/s0254-6272(13)60012-6.
To examine the clinical effects of a mixture of Chinese Yam and epimedium in patients with stable moderate or severe chronic obstructive pulmonary disease (COPD).
Forty-nine patients with COPD were randomly allocated to a group whose usual treatment was supplemented with oral Chinese yam-epimedium mixture, or a control group given placebo. For each patient, body mass index, airflow obstruction, dyspnea, and exercise capacity were measured and converted into the BODE index before treatment and at one and three months after initiation of treatment. Participants also completed the St. George's respiratory questionnaire (SGRQ) at the same intervals.
After one month, improvements were seen in the BODE index and SGRQ of participants taking Chinese yam-epimedium mixture compared to controls. There were statistically significant differences in the SGRQ: three of its components and the total SGRQ scores were significantly decreased (P < 0.05), respiratory symptom scores had improved (P < 0.01), and the dyspnea component of the BODE index had significantly decreased (P < 0.05). Similar improvements were observed after three months of treatment, but exercise tolerance had also improved: the six-minute walking distance had significantly increased (P < 0.05) in the treatment group when compared with controls.
Chinese yam-epimedium mixture can significantly improve dyspnea, exercise capacity, and the quality of life of patients with stable moderate or severe COPD.
观察山药和淫羊藿混合物在稳定期中重度慢性阻塞性肺疾病（COPD）患者中的临床疗效。
将 49 例 COPD 患者随机分为两组，一组在常规治疗的基础上加用口服山药-淫羊藿混合物，另一组给予安慰剂。在治疗前和治疗 1 个月、3 个月时，对每位患者的体重指数、气流阻塞、呼吸困难和运动能力进行测量，并转换为 BODE 指数。患者还在相同的时间间隔内完成圣乔治呼吸问卷（SGRQ）。
治疗 1 个月后，服用山药-淫羊藿混合物的患者的 BODE 指数和 SGRQ 较对照组有所改善。SGRQ 的三个组成部分和总 SGRQ 评分均有显著降低（P<0.05），呼吸道症状评分有所改善（P<0.01），BODE 指数的呼吸困难组成部分也有显著降低（P<0.05），差异均有统计学意义。治疗 3 个月后也观察到类似的改善，但运动耐量也有所提高：与对照组相比，治疗组的 6 分钟步行距离显著增加（P<0.05）。
山药-淫羊藿混合物可显著改善稳定期中重度 COPD 患者的呼吸困难、运动能力和生活质量。
